Investigational drugs for HIV: trends, opportunities and key players

Ronald J. Overmars, Zoë Krullaars, Thibault Mesplède*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

1 Citation (Scopus)


Introduction: Since the first antiretroviral drug was described, the field of HIV treatment and prevention has undergone two drug-based revolutions: the first one, enabled by the virtually concomitant discovery of non-nucleoside reverse transcriptase and protease inhibitors, was the inception of combined antiretroviral therapy. The second followed the creation of integrase strand-transfer inhibitors with improved safety, potency, and resistance profiles. Long-acting antiretroviral drugs, including broadly neutralizing antibodies, now offer the opportunity for a third transformational change in HIV management. Areas covered: Our review focused on HIV treatment and prevention with investigational drugs that offer the potential for infrequent dosing, including drugs not yet approved for clinical use. We also discussed approved drugs for which administration modalities or formulations are being optimized. We performed a literature search in published manuscripts, conference communications, and registered clinical trials. Expert opinion: While the field focuses on extending dosing intervals, we identify drug tissue penetration as an understudied opportunity to improve HIV care. We repeat that self-administration remains an essential milestone to reach the full potential of long-acting drugs. Treatments and prevention strategies based on broadly neutralizing antibodies require a deeper understanding of their antiretroviral properties.

Original languageEnglish
Pages (from-to)127-139
Number of pages13
JournalExpert Opinion on Investigational Drugs
Issue number2
Early online date15 Feb 2023
Publication statusPublished - 2023

Bibliographical note

Publisher Copyright: © 2023 Informa UK Limited, trading as Taylor & Francis Group.


Dive into the research topics of 'Investigational drugs for HIV: trends, opportunities and key players'. Together they form a unique fingerprint.

Cite this